The Heartworm Chewables market growth remains anchored by North America, which commands roughly 45% of global sales, driven by high pet‑ownership rates, proactive veterinary preventive programs, and robust reimbursement policies. Europe follows with a 20% share, where stringent animal health regulations, mature distribution networks, and rising demand for oral parasite‑control solutions sustain steady performance. Asia Pacific, projected as the fastest‑growing region, holds about 25% of the market and is propelled by rapid urbanization, expanding middle‑class pet owners, and increasing investment in veterinary infrastructure across China, India, and Southeast Asia. Latin America contributes an estimated 5%, supported by growing awareness of heartworm risks, government‑backed vaccination campaigns, and a surge in boutique pet‑care outlets. The Middle East & Africa also accounts for roughly 5%, where emerging pet markets, improving veterinary education, and new import‑friendly policies are beginning to unlock demand. Across all territories, the regional forecast underscores a shift toward convenient chewable formulations, reinforced by digital veterinary tele‑consultations and heightened consumer preference for compliance‑friendly dosing. Stakeholders should monitor regulatory harmonization and supply‑chain resilience as critical levers for sustaining momentum in the regional forecast of heartworm chewables.
